KMTS Stock Analysis: Kestra Medical | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.575m USD | 12M Return: 71.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.54M
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS) is a Kirkland, Washington-based wearable medical device and digital healthcare company focused on cardiovascular disease. Founded in 2014 and listed on NASDAQ in March 2025, the company sits within the Health Care Equipment sub-industry of the broader medical devices sector.
Its core offering is the Cardiac Recovery System platform, which combines monitoring, therapeutic intervention, digital health tools, and patient support services in a single integrated solution. The platforms flagship product is the ASSURE WCD, a wearable cardioverter defibrillator designed to protect patients at elevated risk of sudden cardiac arrest during a defined recovery period.
Kestra pairs its hardware with a suite of connected digital services aimed at improving engagement between patients and providers. This hardware-plus-software-and-services model is characteristic of the connected health segment of medical devices, where recurring service and data components complement the sale of the underlying device.
- ASSURE WCD adoption accelerates revenue growth post-IPO
- Competition from ZOLL LifeVest pressures market share and pricing
- Reimbursement coverage decisions drive prescriber adoption rates
| Net Income: -144.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA 50.42 > 1.0 |
| NWC/Revenue: 323.9% < 20% (prev 59.32%; Δ 264.5% < -1%) |
| CFO/TA -0.23 > 3% & CFO -86.7m > Net Income -144.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.8m) vs 12m ago 6.68% < -2% |
| Gross Margin: 48.75% > 18% (prev 34.15%; Δ 14.60% > 0.5%) |
| Asset Turnover: 34.36% > 50% (prev 48.74%; Δ -14.38% > 0%) |
| Interest Coverage Ratio: -18.26 > 6 (EBIT TTM -136.2m / Interest Expense TTM 7.46m) |
| A: 0.71 (Total Current Assets 314.1m - Total Current Liabilities 42.9m) / Total Assets 379.3m |
| B: -1.62 (Retained Earnings -613.0m / Total Assets 379.3m) |
| C: -0.56 (EBIT TTM -136.2m / Avg Total Assets 243.7m) |
| D: 3.15 (Book Value of Equity 288.0m / Total Liabilities 91.4m) |
| Altman-Z'' = -1.03 = CCC |
| DSRI: 1.01 (Receivables 12.7m/7.93m, Revenue 83.7m/52.6m) |
| GMI: 0.70 (GM 34.15% / 48.75%) |
| AQI: 0.48 (AQ_t 0.02 / AQ_t-1 0.04) |
| SGI: 1.59 (Revenue 83.7m / 52.6m) |
| TATA: -0.15 (NI -144.8m - CFO -86.7m) / TA 379.3m) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 25.99 with a total of 449,719 shares traded. Over the past week, the price has changed by -3.67%, over one month by +33.69%, over three months by +45.44% and over the past year by +71.10%.
Current recommended Stop Loss: 22.70 (which is 12.7% or 2 ATR below the current price).
Kestra Medical has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy KMTS.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.7 | 6.6% |
P/S = 18.8114
P/B = 5.3389
Revenue TTM = 83.7m USD
EBIT TTM = -136.2m USD
EBITDA TTM = -128.0m USD
Long Term Debt = 42.3m USD (from longTermDebt, last quarter)
Short Term Debt = 10.0k USD (from shortTermDebt, last quarter)
Debt = 50.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.29m
Net Debt = -240.5m USD (calculated: Debt 50.8m - CCE 291.3m)
Enterprise Value = 1.33b USD (1.57b + Debt 50.8m - CCE 291.3m)
Interest Coverage Ratio = -18.26 (Ebit TTM -136.2m / Interest Expense TTM 7.46m)
EV/FCF = -11.12x (Enterprise Value 1.33b / FCF TTM -120.0m)
FCF Yield = -8.99% (FCF TTM -120.0m / Enterprise Value 1.33b)
FCF Margin = -143.3% (FCF TTM -120.0m / Revenue TTM 83.7m)
Net Margin = -173.0% (Net Income TTM -144.8m / Revenue TTM 83.7m)
Gross Margin = 48.75% ((Revenue TTM 83.7m - Cost of Revenue TTM 42.9m) / Revenue TTM)
Gross Margin QoQ = 52.57% (prev 50.63%)
Tobins Q-Ratio = 3.52 (Enterprise Value 1.33b / Total Assets 379.3m)
Interest Expense / Debt = 14.68% (Interest Expense 7.46m / Debt 50.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -107.6m (EBIT -136.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.32 (Total Current Assets 314.1m / Total Current Liabilities 42.9m)
Debt / Equity = 0.18 (Debt 50.8m / totalStockholderEquity, last quarter 288.0m)
Debt / EBITDA = 1.88 (negative EBITDA) (Net Debt -240.5m / EBITDA -128.0m)
Debt / FCF = 2.00 (negative FCF - burning cash) (Net Debt -240.5m / FCF TTM -120.0m)
Total Stockholder Equity = 210.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.44% (Net Income -144.8m / Total Assets 379.3m)
RoE = -68.83% (Net Income TTM -144.8m / Total Stockholder Equity 210.4m)
RoCE = -53.91% (EBIT -136.2m / Capital Employed (Equity 210.4m + L.T.Debt 42.3m))
RoIC = -32.39% (negative operating profit) (NOPAT -107.6m / Invested Capital 332.2m)
WACC = 9.74% (E(1.57b)/V(1.63b) * Re(9.68%) + D(50.8m)/V(1.63b) * Rd(14.68%) * (1-Tc(0.21)))
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.03 | Cagr: 2.92%
[DCF] Fair Price = unknown (Cash Flow -120.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.42 | # QB: 0
Revenue Correlation: 98.92 | Revenue CAGR: 180.0% | SUE: N/A | # QB: 0
EPS current Quarter (2026-07-31): EPS=-0.54 | Chg30d=+0.00% | Revisions=+0% | Analysts=2
EPS current Year (2026-04-30): EPS=-2.33 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+40.4% | GrowthRev=+55.4%
EPS next Year (2027-04-30): EPS=-2.14 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+8.2% | GrowthRev=+42.9%
[Analyst] Revisions Ratio: +0% (up=3, down=3)